Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pruvanserin augmentation of SSRI therapy in major depressive disorder with inadequate antidepressant response
2005-002430-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing SSRI + pruvanserin with SSRI + placebo (2 arms). Primary endpoint: Change from baseline in HAMD-17 total score. Started Aug 2005; status: completed.
02
Drugs
pruvanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-002430-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002430-34.